Marketers Sponsored by
Johnson & Johnson announced sales of $17.6 billion for the third quarter of 2013, an increase of 3.1% as compared to the third quarter of 2012. Operational results increased 4.7%, and the negative impact of currency was 1.6%. Domestic sales increased 1.7% while international sales increased 4.2%, reflecting operational growth of 7.1% and a negative currency impact of 2.9%.
“Our third-quarter results reflect the solid, demonstrable results in achieving our near-term priorities while also advancing our longer-term strategic growth drivers,” said Alex Gorsky, chairman and CEO of J&J. “Our key products and successful new product launches delivered strong growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of new drug applications, and execution of strategic collaborations. Our investments further strengthen our ability to deliver sustainable growth and bring meaningful innovations to patients and consumers.”
Additionally, J&J also announced it has increased its earnings guidance for full-year 2013 to $5.44–5.49 per share. The company’s guidance excludes the impact of special items.
J&J's worldwide consumer division sales were at $3.6 billion for the third quarter 2013, representing an increase of 0.8% versus the prior year and consisting of an operational increase of 2% and a negative impact from currency of 1.2%. Domestic sales increased 0.9%, and international sales increased 0.8%, which reflected an operational increase of 2.6% and a negative currency impact of 1.8%.
Positive contributors to operational results for the worldwide consumer division were U.S. sales of Tylenol and Motrin analgesics; upper respiratory over the counter medicines; and Aveeno skin care products and international baby care products.
Much of J&J's sales growth for the quarter was pushed by its worldwide pharmaceuticals division, which saw sales of $7 billion for the quarter, a 9.9% increase versus the third quarter in 2012.